0001193805-24-000320.txt : 20240306 0001193805-24-000320.hdr.sgml : 20240306 20240306215046 ACCESSION NUMBER: 0001193805-24-000320 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240304 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Whaley Glenn CENTRAL INDEX KEY: 0001724623 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36201 FILM NUMBER: 24727977 MAIL ADDRESS: STREET 1: C/O PERNIX THERAPEUTICS HOLDINGS, INC. STREET 2: 10 NORTH PARK PLACE, SUITE 201 CITY: MORRISTOWN STATE: NJ ZIP: 07960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNIC, INC. CENTRAL INDEX KEY: 0001280776 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 562358443 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1200 AVENUE OF THE AMERICAS STREET 2: SUITE 200 CITY: NEW YORK STATE: X1 ZIP: 10036 BUSINESS PHONE: (332) 255-9818 MAIL ADDRESS: STREET 1: 1200 AVENUE OF THE AMERICAS STREET 2: SUITE 200 CITY: NEW YORK STATE: X1 ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: VITAL THERAPIES INC DATE OF NAME CHANGE: 20040219 4 1 e619334_4-whaley.xml FORM 4 X0508 4 2024-03-04 0 0001280776 IMMUNIC, INC. IMUX 0001724623 Whaley Glenn 1200 AVENUE OF THE AMERICAS, SUITE 200 NEW YORK NY 10036 0 1 0 0 Chief Financial Officer 0 Stock Option 7.37 2024-03-04 4 D 0 15000 D 2029-12-01 Common Stock 15000 0 D Stock Option 8.84 2024-03-04 4 D 0 15000 D 2030-04-29 Common Stock 15000 0 D Stock Option 12.30 2024-03-04 4 D 0 30000 D 2030-07-01 Common Stock 30000 0 D Stock Option 15.72 2024-03-04 4 D 0 40000 D 2031-03-01 Common Stock 40000 0 D Stock Option 10.73 2024-03-04 4 D 0 70000 D 2032-01-03 Common Stock 70000 0 D Stock Option 10.88 2024-03-04 4 D 0 40000 D 2032-03-10 Common Stock 40000 0 D Stock Option 3.40 2024-03-04 4 D 0 10000 D 2032-06-15 Common Stock 10000 0 D Stock Option 1.72 2024-03-04 4 A 0 220000 A Common Stock 220000 220000 D On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. /s/ Glenn Whaley 2024-03-06